E113485 - GyroNuQ
| Reference number | |
| Coordinator | Gyros Protein Technologies AB |
| Funding from Vinnova | SEK 2 159 787 |
| Project duration | September 2019 - February 2021 |
| Status | Completed |
| Venture | Eurostars |
Important results from the project
Screening for lung cancer with low-dose computed tomography for people at risk saves lives but is limited by the frequency of false positive results. We will develop a triage test for positive individuals by combining low-cost Nu.Q immunoassay of circulating cell-free nucleosomes with a high-performance automated and parallel assay platform - Gyrolab®. This allows multiple reproducible measurements in parallel to maximize clinical sensitivity which overcomes potential cross-response constraints with conventional multiplexing
Expected long term effects
The overall goal for the entire project is to be able to identify epigenetic biomarkers (nucleosomes) with a new analysis methodology. This would mean new opportunities in the field of cancer diagnostics. A sub-task is to be able to measure lower concentration levels that are clinically relevant. The project has delivered a new macro / microfluidic CD with improved sensitivity.
Approach and implementation
A macro / microfluidic CD for use in the immunoassay field has been developed, from the early idea phase to a product that can be used in several different fields of application. Several model- and nucleosome-assays have been evaluated and they show 3-4 times increased sensitivity. The CD is available in the project for nucleosome analysis and has been launched as a product (Gyrolab Bioaffy 4000) that can be used in the automatic immunoassay system, Gyrolab®.